Evoq Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2025 ,inter alia, to consider and approve Pursuant to regulation 30 and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evoq Remedies' Board met on 18 April 2025 but postponed key agenda items to a fresh meeting on 25 April 2025 at 3:00 PM. The rescheduled meeting will consider acquiring up to 51% of Poshan Nutriwell Private Limited (PNPL) by issuing equity shares through a share-swap (non-cash preferential issue). It will also consider raising up to Rs. 99 Crores by issuing convertible warrants to non-promoter entities on a preferential basis, subject to shareholder approval. Additionally, the Board will approve the draft notice for an Extra-Ordinary General Meeting (EGM) of shareholders. The trading window for designated persons is closed from 18 April until 48 hours after the meeting concludes.
If approved, this could be a significant transformation for the small-cap company – a 51% acquisition via share swap signals expansion into the nutrition/health segment, while the Rs. 99 Crore warrant issue could dilute existing shareholders and bring in new non-promoter investors. Shareholders should watch the 25 April outcome closely as it may materially change the company's size, capital structure, and business focus.